Case Report of Everolimus-Associated DKA in a Patient with Metastatic Renal Cell Carcinoma.
- Author:
Lee Kyung KIM
1
;
Chang Ho AHN
;
Jie Eun LEE
;
Chan Hyeon JUNG
;
Bo Kyung KOO
;
Min Kyong MOON
Author Information
1. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. mkmoon@snu.ac.kr
- Publication Type:Case Report
- Keywords:
Everolimus;
DKA;
Hyperglycemia;
Insulin resistance;
Metastatic renal cell carcinoma
- MeSH:
Blood Glucose;
Breast Neoplasms;
Carcinoma, Renal Cell*;
Diabetic Ketoacidosis;
Humans;
Hypercholesterolemia;
Hyperglycemia;
Hypertriglyceridemia;
Insulin;
Insulin Resistance;
Neuroendocrine Tumors;
Sirolimus;
Everolimus
- From:Korean Journal of Medicine
2014;86(6):761-765
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Everolimus, an inhibitor of the mammalian target of the rapamycin (mTOR) pathway, is widely used as an immunosuppressant for the prevention of organ rejection following transplant and to treat metastatic clear-cell type renal cell carcinoma (RCC), breast cancer, and pancreatic neuroendocrine tumors. Everolimus commonly induces metabolic abnormalities such as hyperglycemia, hypercholesterolemia, and hypertriglyceridemia due to concomitant increases in blood glucose levels via the induction of insulin resistance and a decrease in beta cell function, which both lead to insulin deficiency. Although abnormal blood glucose levels are observed in more than 50% of patients treated with Everolimus, hyperglycemia exceeding 500 mg/dL is not common and there have been no reports of Everolimus-induced acute hyperglycemic crisis conditions. Here, a novel case of Everolimus-associated diabetic ketoacidosis (DKA) in a patient with RCC is reported.
